F-star CEO: Revamped Merck KGaA Pact Is First Step In New Corp Direction

F-star CEO tells Scrip reconfiguring biotech’s pact with Merck KGaA on oncology asset FS118 is UK group’s first big move towards a wholly owned portfolio strategy.

New_Direction
F-star is building a proprietary pipeline while retaining collaborations • Source: Shutterstock

A revision to F-star’s agreement with Merck KGaA has propelled the UK-based bispecific antibody specialist on a new course to develop a proprietary pipeline, its CEO said.

The 2017 immuno-oncology R&D collaboration with Merck KGaA granted the German group exclusive development and commercial rights to five novel...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip